The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Posts: 10,737
Just to say for those unaware of this ..
Check out Synairgen .. If P3 is a success then many multiples of current SP
Check out Broker predictions... There are some well informed posters
on the SNG board here.....Good Luck..!! Check out the Buys on Friday 11/02
Over £1million in last 25mins... Polygon have recently increased to over 18%..
Posts: 10,737
Interferon-ß acts directly on T cells to prolong allograft survival by enhancing regulatory T cell i12 Feb 2022 20:12
Looks to be a newly published study, full details behind a paywall, but the summary seems pretty good if you've got a product that can deliver INFb to the human body without the side effects associated with subcutaneous administration...
" Highlights
•
IFNß synergizes with CTLA-4 Ig to prolong allograft survival by promoting Treg cells
•
IFNß directly acts on T cells to enhance Treg cell induction
•
IFNß activates STAT1 signaling to promote P300 expression and increase Foxp3 acetylation
Summary
Type I interferons (IFNs) are pleiotropic cytokines with potent antiviral properties that also promote protective T cell and humoral immunity. Paradoxically, type I IFNs, including the widely expressed IFNß, also have immunosuppressive properties, including promoting persistent viral infections and treating T-cell-driven, remitting-relapsing multiple sclerosis. Although associative evidence suggests that IFNß mediates these immunosuppressive effects by impacting regulatory T (Treg) cells, mechanistic links remain elusive. Here, we found that IFNß enhanced graft survival in a Treg-cell-dependent murine transplant model. Genetic conditional deletion models revealed that the extended allograft survival was Treg cell-mediated and required IFNß signaling on T cells. Using an in silico computational model and analysis of human immune cells, we found that IFNß directly promoted Treg cell induction via STAT1- and P300-dependent Foxp3 acetylation. These findings identify a mechanistic connection between the immunosuppressive effects of IFNß and Treg cells, with therapeutic implications for transplantation, autoimmunity, and malignancy."
https://www.cell.com/immunity/ppt/S1074-7613(22)00040-1.ppt
Credit to Brand on SNG Board..
Posts: 10,737
RE: NIH director tweeting about interferon11 Feb 2022 07:13
And then this activ2 presentation Monday which is an NIH backed trial. It’s as if they are prepping/waving the flag before the day hmmmm https://www.eurekalert.org/news-releases/942698
gggg21
Posted in: SNG
Posts: 8,927
Price: 190.50
No Opinion
NIH director tweeting about interferon11 Feb 2022 06:58
https://twitter.com/nihdirector/status/1491887417535737860?s=21
In ~10% of cases, #SARSCoV2 infection triggers oxygen-deficient #COVID19 pneumonia. New #NIH-funded research suggests insufficient type 1 IFN immunity in the respiratory tract may account for viral spread, leading to pulmonary & systemic inflammation.
CREDIT GGG21 ON SNG board..